USP comments to FDA on Docket No. FDA–2021–D–0241 for ‘‘Inspection of Injectable Products for Visible Particulates’’ . Comments were submitted in 2022.
USP comments to FDA on Docket No. FDA–2021–D–0241 for ‘‘Inspection of Injectable Products for Visible Particulates’’ . Comments were submitted in 2022.